

JUNIPER PHARMACEUTICALS INC  
Form SC TO-T  
July 17, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE TO**  
**Tender Offer Statement under Section 14(d)(1) or 13(e)(1)**  
**of the Securities Exchange Act of 1934**

**Juniper Pharmaceuticals, Inc.**

**(Name of Subject Company (Issuer))**

**Catalent Boston, Inc.**

**A wholly owned subsidiary of**

**Catalent Pharma Solutions, Inc.**

**A wholly owned subsidiary of**

**Catalent, Inc.**

**(Names of Filing Persons (Offeror))**

**Common Stock, par value \$0.01 per share**

**(Title of Class of Securities)**

**48203L107**

**(CUSIP Number of Class of Securities)**

**Steven L. Fasman, Esq.**

**Senior Vice President, General Counsel and Secretary**

**Catalent, Inc.**

**14 Schoolhouse Road**

**Somerset, New Jersey 08873**

**(732) 537-6200**

**(Name, Address and Telephone Numbers of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)**

*Copy to:*

**Richard A. Silfen, Esq.**

**Barry Steinman, Esq.**

**Peter D. Visalli, Esq.**

**Duane Morris LLP**

**30 South 17th Street**

**Philadelphia, Pennsylvania 19103**

**(215) 979-1000**

**CALCULATION OF FILING FEE**

**Transaction Valuation<sup>(1)</sup>**

\$139,613,514.00

**Amount of Filing Fee<sup>(2)</sup>**

\$17,381.88

(1)

Edgar Filing: JUNIPER PHARMACEUTICALS INC - Form SC TO-T

Estimated solely for purposes of calculating the filing fee. The transaction valuation was calculated as the sum of (i) 11,104,757 outstanding shares of common stock, par value \$0.01 per share (the Shares ), of Juniper Pharmaceuticals, Inc. (excluding unvested restricted stock which is addressed in clause (iii)) multiplied by \$11.50, (ii) 1,776,900 Shares issuable pursuant to outstanding stock options that have vested (or are anticipated to vest prior to the completion of the transaction) multiplied by \$4.95 (which is \$11.50 minus the weighted average exercise price for such options of \$6.55 per Share) and (iii) 270,709 Shares issuable pursuant to outstanding unvested restricted stock awards that are anticipated to vest prior to the completion of the transaction multiplied by \$11.50. The calculation of the filing fee is based on information provided by Juniper Pharmaceuticals, Inc. as of July 12, 2018, the most recent practicable date.

- (2) The filing fee was calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #1 for Fiscal Year 2018, issued August 24, 2017, by multiplying the transaction value by .0001245.

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) of the Securities Exchange Act of 1934 and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid: None  
Form or Registration No.: Not applicable

Filing Party: Not applicable  
Date Filed: Not applicable

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

- third-party tender offer subject to Rule 14d-1.
- issuer tender offer subject to Rule 13e-4.
- going-private transaction subject to Rule 13e-3.
- amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

This Tender Offer Statement on Schedule TO (this Schedule TO ) is being filed by Catalent Boston, Inc., a Delaware corporation (Purchaser ) and wholly owned subsidiary of Catalent Pharma Solutions, Inc., a Delaware corporation (Parent ) and wholly owned subsidiary of Catalent, Inc., a Delaware corporation (Catalent ), and relates to the offer by Purchaser to purchase all outstanding shares of common stock, par value \$0.01 per share (the Shares ), of Juniper Pharmaceuticals, Inc., a Delaware corporation (the Company ), at a price per Share of \$11.50 (such price as it may be amended from time to time in accordance with the Merger Agreement (as defined below), the Offer Price ), net to the seller in cash, without any interest, but subject to and reduced by any required withholding of taxes upon the terms and subject to the conditions set forth in the Offer to Purchase (together with any amendment or supplement hereto, the Offer to Purchase ) and in the related Letter of Transmittal (together with any amendment or supplement thereto, the Letter of Transmittal and, together with the Offer to Purchase, the Offer ), which are annexed to and filed with this Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. Unless otherwise indicated, references to sections in this Schedule TO are references to sections of the Offer to Purchase. The Agreement and Plan of Merger, dated as of July 2, 2018 (together with any amendment or supplement thereto, the Merger Agreement ), among Parent, Purchaser and the Company, a copy of which agreement is filed with this Schedule TO as Exhibit (d)(1), is incorporated herein by reference with respect to Items 4 through 11 of this Schedule TO.

#### **ITEM 1. SUMMARY TERM SHEET.**

The information set forth in the section of the Offer to Purchase titled Summary Term Sheet is incorporated herein by reference.

#### **ITEM 2. SUBJECT COMPANY INFORMATION.**

(a) The name of the subject company and the issuer of the securities subject to the Offer is Juniper Pharmaceuticals, Inc. Its principal executive office is located at 33 Arch Street, Suite 3110, Boston, Massachusetts 02110.

(b) This Schedule TO relates to the Shares of the Company. According to the Company, as of July 12, 2018 (the most recent practicable date), there were 11,104,757 Shares outstanding.

(c) The information concerning the principal market in which the Shares are traded and high and low closing prices for the Shares in the principal market in which the Shares are traded set forth in Section 6 ( Price Range of Shares; Dividends ) of the Offer to Purchase is incorporated herein by reference.

#### **ITEM 3. IDENTITY AND BACKGROUND OF FILING PERSON.**

(a), (b), (c) The filing companies of this Schedule TO are Catalent, Parent and Purchaser (the Filing Persons ).

Each of Catalent s, Parent s and Purchaser s principal executive office is located at 14 Schoolhouse Road, Somerset, New Jersey 08873, and the telephone number of each is (732) 537-6200.

The information regarding the Filing Persons set forth in Section 9 ( Certain Information Concerning the Filing Persons ) of the Offer to Purchase and Schedule A of the Offer to Purchase is incorporated herein by reference.

#### **ITEM 4. TERMS OF THE TRANSACTION.**

(a) The information set forth in the Offer to Purchase relating to this third-party tender offer is incorporated herein by reference.

**ITEM 5. PAST CONTACTS, TRANSACTIONS, NEGOTIATIONS AND AGREEMENTS.**

(a), (b) The information set forth in the section of the Offer to Purchase titled Summary Term Sheet and Section 8 ( Certain Information Concerning the Company ), Section 9 ( Certain Information Concerning the

Filing Persons ), Section 10 ( Background of the Offer; Contacts with the Company ) and Section 11 ( Purpose of the Offer and Plans for the Company; Summary of the Merger Agreement and Certain Other Agreements ) of the Offer to Purchase is incorporated herein by reference.

**ITEM 6. PURPOSES OF THE TRANSACTION AND PLANS OR PROPOSALS.**

(a), (c)(1), (4-7) The information set forth in the sections of the Offer to Purchase titled Summary Term Sheet and Introduction and Section 7 ( Possible Effects of the Offer on the Market for the Shares; NASDAQ Listing; Exchange Act Registration and Margin Regulations ), Section 10 ( Background of the Offer; Contacts with the Company ), Section 11 ( Purpose of the Offer and Plans for the Company; Summary of the Merger Agreement and Certain Other Agreements ), Section 12 ( Source and Amount of Funds ) and Section 14 ( Dividends and Distributions ) of the Offer to Purchase is incorporated herein by reference.

(c)(2-3) Not applicable.

**ITEM 7. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.**

(a) The information set forth in the section of the Offer to Purchase titled Summary Term Sheet and Section 12 ( Source and Amount of Funds ) of the Offer to Purchase is incorporated herein by reference.

(b) The Offer is not subject to a financing condition.

(d) The information set forth in the section of the Offer to Purchase titled Summary Term Sheet and Section 12 ( Source and Amount of Funds ) of the Offer to Purchase is incorporated herein by reference.

**ITEM 8. INTEREST IN SECURITIES OF THE SUBJECT COMPANY.**

The information set forth in Section 9 ( Certain Information Concerning the Filing Persons ), Section 10 ( Background of the Offer; Contacts with the Company ) and Section 11 ( Purpose of the Offer and Plans for the Company; Summary of the Merger Agreement and Certain Other Agreements ) is incorporated herein by reference.

**ITEM 9. PERSONS/ASSETS, RETAINED, EMPLOYED, COMPENSATED OR USED.**

(a) The information set forth in Section 10 ( Background of the Offer; Contacts with the Company ) and Section 16 ( Fees and Expenses ) of the Offer to Purchase is incorporated herein by reference.

**ITEM 10. FINANCIAL STATEMENTS.**

Not applicable. In accordance with the instructions to Item 10 of this Schedule TO, the financial statements are not considered material because:

(i) the consideration offered consists solely of cash;

(ii) the Offer is not subject to any financing condition; and

(iii) the Offer is for all outstanding securities of the subject class.

**ITEM 11. ADDITIONAL INFORMATION.**

(a)(1) The information set forth in the section of the Offer to Purchase titled "Summary Term Sheet" and in Section 10 ( "Background of the Offer; Contacts with the Company" ) and Section 11 ( "Purpose of the Offer and Plans for the Company; Summary of the Merger Agreement and Certain Other Agreements" ) of the Offer to Purchase is incorporated herein by reference.

(a)(2) The information set forth in Section 15 ( "Certain Legal Matters" ) of the Offer to Purchase is incorporated herein by reference.

(a)(3) The information set forth in Section 15 ( Certain Legal Matters ) of the Offer to Purchase is incorporated herein by reference.

(a)(4) The information set forth in Section 7 ( Possible Effects of the Offer on the Market for the Shares; NASDAQ Listing; Exchange Act Registration and Margin Regulations ) of the Offer to Purchase is incorporated herein by reference.

(a)(5) The information set forth in Section 15 ( Certain Legal Matters ) of the Offer to Purchase is incorporated herein by reference.

(c) The information set forth in the Offer to Purchase is incorporated herein by reference.

## ITEM 12. EXHIBITS.

- (a)(1)(A) Offer to Purchase, dated July 17, 2018
- (a)(1)(B) Form of Letter of Transmittal
- (a)(1)(C) Form of Notice of Guaranteed Delivery
- (a)(1)(D) Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees
- (a)(1)(E) Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees
- (a)(1)(F) Summary Advertisement, published July 17, 2018 in the *Wall Street Journal*
- (a)(2) Not applicable
- (a)(3) Not applicable
- (a)(4) Not applicable
- (a)(5)(A) Press Release issued on July 3, 2018 by Catalent, Inc. (incorporated by reference to Exhibit 99.1 to the Tender Offer Statement on Schedule TO filed by Catalent with the Securities and Exchange Commission (the Commission ) on July 9, 2018)
- (a)(5)(B) Presentation to the Company, dated July 3, 2018 (incorporated by reference to Exhibit 99.1 to the Tender Offer Statement on Schedule TO filed by Catalent with the Commission on July 3, 2018)
- (a)(5)(C) Letter from John Chiminski, Chairman and CEO of Catalent to the Company's Employees, dated July 3, 2018 (incorporated by reference to Exhibit 99.2 to the Tender Offer Statement on Schedule TO filed by Catalent with the Commission on July 3, 2018)
- (b) Not applicable
- (d)(1) Agreement and Plan of Merger, dated as of July 2, 2018, among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Catalent with the Commission on July 3, 2018)
- (d)(2) Confidentiality Agreement, dated as of February 16, 2018, between Catalent Pharma Solutions, LLC and Juniper Pharmaceuticals, Inc. (incorporated by reference to Exhibit (e)(2) to the Schedule 14D-9 filed by the Company with the Commission on July 17, 2018)



- (g) Not applicable
- (h) Not applicable

**ITEM 13. INFORMATION REQUIRED BY SCHEDULE 13E-3.**

Not applicable.

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 17, 2018

**Catalent, Inc.**

By: /s/ Steven L. Fasman  
Name: Steven L. Fasman  
Title: Senior Vice President & General  
Counsel and Secretary

**Catalent Pharma Solutions, Inc.**

By: /s/ Steven L. Fasman  
Name: Steven L. Fasman  
Title: Senior Vice President & General  
Counsel and Secretary

**Catalent Boston, Inc.**

By: /s/ Steven L. Fasman  
Name: Steven L. Fasman  
Title: Senior Vice President & General  
Counsel and Secretary

**EXHIBIT INDEX**

- (a)(1)(A) Offer to Purchase, dated July 17, 2018
- (a)(1)(B) Form of Letter of Transmittal
- (a)(1)(C) Form of Notice of Guaranteed Delivery
- (a)(1)(D) Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees
- (a)(1)(E) Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees
- (a)(1)(F) Summary Advertisement, published July 17, 2018 in the *Wall Street Journal*
- (a)(2) Not applicable
- (a)(3) Not applicable
- (a)(4) Not applicable
- (a)(5)(A) Press Release issued on July 3, 2018 by Catalent, Inc. (incorporated by reference to Exhibit 99.1 to the Tender Offer Statement on Schedule TO filed by Catalent with the Securities and Exchange Commission (the Commission ) on July 9, 2018)
- (a)(5)(B) Presentation to the Company, dated July 3, 2018 (incorporated by reference to Exhibit 99.1 to the Tender Offer Statement on Schedule TO filed by Catalent with the Commission on July 3, 2018)
- (a)(5)(C) Letter from John Chiminski, Chairman and CEO of Catalent to the Company's Employees, dated July 3, 2018 (incorporated by reference to Exhibit 99.2 to the Tender Offer Statement on Schedule TO filed by Catalent with the Commission on July 3, 2018)
- (b) Not applicable
- (d)(1) Agreement and Plan of Merger, dated as of July 2, 2018, among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Catalent with the Commission on July 3, 2018)
- (d)(2) Confidentiality Agreement, dated as of February 16, 2018, between Catalent Pharma Solutions, LLC and Juniper Pharmaceuticals, Inc. (incorporated by reference to Exhibit (e)(2) to the Schedule 14D-9 filed by the Company with the Commission on July 17, 2018)
- (g) Not applicable
- (h) Not applicable

=>

Cosmopolitan Center (d)

9,465 2,581 (4,562) (1,189) 4,903 1,392 6,295 1,369 2006 24 years

Atlanta, GA



Edgar Filing: JUNIPER PHARMACEUTICALS INC - Form SC TO-T

Total Office

\$341,011 \$74,767 \$384,549 \$(9,128) \$363,711 \$65,639 \$748,260 \$813,899 \$215,817

S-1

Table of Contents

SCHEDULE III

(Page 2 of 4)

## COUSINS PROPERTIES INCORPORATED AND SUBSIDIARIES

## REAL ESTATE AND ACCUMULATED DEPRECIATION

DECEMBER 31, 2011

(in thousands)

Description/Metropolitan Area	Encumbrances	Improvements	Improvements	Costs Capitalized Subsequent to			Total (a)	Accumulated Depreciation (b)	Construction/ Renovation Date	Date Acquired	Life on Which Depreciation in 2011 Statement of Operations is Computed (b)	
				Initial Cost to Company	Acquisition	Gross Amount at Which Carried at Close of Period						
		Land and Buildings	Land and Improvements less Cost	Building and Improvements less Cost	Building and Improvements less Cost	Building and Improvements less Cost						
<b>OPERATING PROPERTIES</b>												
<b>Retail</b>												
The Avenue Forsyth Suburban Atlanta, GA	\$	\$ 22,848	\$	\$ 10,904	\$ 99,185	\$ 33,752	\$ 99,185	\$ 132,937	\$ 17,585	2009	2007	30 years
The Avenue Collierville Suburban Memphis, TN		11,470		(1,675)	84,019	9,795	84,019	93,814	29,415	2004	2004	30 years
The Avenue Webb Gin Suburban Atlanta, GA		11,583		(2,275)	67,058	9,308	67,058	76,366	20,503	2005	2005	30 years
Tiffany Springs MarketCenter Kansas City, MO		8,174		5,896	43,039	14,070	43,039	57,109	6,153	2009	2007	30 years
<b>Total Retail</b>	<b>\$</b>	<b>\$ 54,075</b>	<b>\$</b>	<b>\$ 12,850</b>	<b>\$ 293,301</b>	<b>\$ 66,925</b>	<b>\$ 293,301</b>	<b>\$ 360,226</b>	<b>\$ 73,656</b>			
<b>Total Operating Properties</b>	<b>\$</b>	<b>\$ 341,011</b>	<b>\$</b>	<b>\$ 128,842</b>	<b>\$ 384,549</b>	<b>\$ 3,722</b>	<b>\$ 657,012</b>	<b>\$ 132,564</b>	<b>\$ 1,041,561</b>	<b>\$ 1,174,125</b>	<b>\$ 289,473</b>	
<b>PROJECTS UNDER DEVELOPMENT</b>												
Mahan Village Callahassee, FL	\$	1	\$	5,377	\$	5,948	\$ 5,377	\$ 5,948	\$ 11,325	\$	2011	2011
<b>LAND HELD FOR INVESTMENT OR FUTURE DEVELOPMENT</b>												
Terminus Atlanta, GA	\$	\$ 18,745	\$	\$ 14,320	\$ (23,165)	\$ 33,065	\$ (23,165)	\$ 9,900	\$		2005	
Round Rock Land Austin, TX		12,802		4,313	(6,915)	17,115	(6,915)	10,200			2005	
15 Peachtree Street		10,164		2,328	(3,642)	12,492	(3,642)	8,850			1996	

Edgar Filing: JUNIPER PHARMACEUTICALS INC - Form SC TO-T

Atlanta, GA							
49 / 555 / 557 Peachtree Street	5,988	6,152	(9,515)	12,140	(9,515)	2,625	2004
Atlanta, GA							
North Point	10,294	29,006	(37,265)	39,300	(37,265)	2,035	1970-1985
Suburban Atlanta, GA							
Land Adjacent to The Avenue Forsyth	11,240	10,875	(18,415)	22,115	(18,415)	3,700	2007
Suburban Atlanta, GA							
Research Park V	4,373	595		4,968		4,968	1998
Austin, TX							
Jefferson Mill Business Park	14,223	9,533	(21,236)	23,756	(21,236)	2,520	2006
Suburban Atlanta, GA							

S-2



Table of Contents

SCHEDULE III

(page 3 of 4)

## COUSINS PROPERTIES INCORPORATED AND SUBSIDIARIES

## REAL ESTATE AND ACCUMULATED DEPRECIATION

DECEMBER 31, 2011

(in thousands)

Description/Metropolitan Area	Initial Cost to Company	Costs Capitalized Subsequent to Acquisition						Total	Accumulated Depreciation	Construction/ Renovation Date	Life on Which Depreciation in 2011 Statement of Operations is Computed (b)
		Land and Improvements	Buildings and Improvements	Land and Improvements less Cost of Sales, Transfers and Other	Building Improvements less Cost of Sales, Transfers and Other	Land and Improvements less Cost of Sales, Transfers and Other	Building Improvements less Cost of Sales, Transfers and Other				
<b>LAND HELD FOR INVESTMENT OR FUTURE DEVELOPMENT (cont'd)</b>											
Blalock Lakes Suburban Atlanta, GA	\$ 9,646	\$ 4	\$ (6,305)	\$ 9,650	\$ (6,305)	\$ 3,345				2008	
King Mill Distribution Park Suburban Atlanta, GA	10,528	6,497	(14,965)	17,025	(14,965)	2,060				2005	
Land Adjacent to The Avenue Collierville Suburban Memphis, TN	7,208	2,052	(7,291)	9,260	(7,291)	1,969				2004	
Wildwood Suburban Atlanta, GA	10,214	5,092	(14,292)	15,306	(14,292)	1,014				1971-1989	
Land Adjacent to The Avenue Webb Gin Suburban Atlanta, GA	946			946		946				2005	
<b>Total Land Held for Investment or Future Development</b>	\$ 126,371	\$ 90,767	\$ (163,006)	\$ 217,138	\$ (163,006)	\$ 54,132					
<b>RESIDENTIAL LOTS</b>											
Callaway Gardens Pine Mountain, GA	\$ 1,584	\$ 16,420	\$ (13,054)	\$ 18,004	\$ (13,054)	\$ 4,950			2006	2006	
Blalock Lakes Suburban Atlanta, GA	17,657	26,897	(37,684)	44,554	(37,684)	6,870			2006	2006	
The Lakes at Cedar Grove Suburban Atlanta, GA	4,720	30,339	(34,559)	35,059	(34,559)	500			2001	2001	
River s Call Suburban Atlanta, GA	2,001	11,037	(12,555)	13,038	(12,555)	483			2000	1971-1989	
Longleaf at Callaway Pine Mountain, GA	180	2,098	6,812	8,910	(8,518)	392			2002	2002	
<b>Total Residential Lots</b>	\$ 180	\$ 28,060	\$ 91,505	\$ (106,370)	\$ 119,565	\$ (106,370)	\$ 13,195				

Edgar Filing: JUNIPER PHARMACEUTICALS INC - Form SC TO-T

<b>OTHER</b>										
10 Terminus Place Atlanta, GA		7,810	72,573	(7,561)	(72,290)	249	283	532	2008	2005
60 North Market Asheville, NC			9,739		(9,634)		105	105		2009
<b>Total Other</b>	\$	\$ 7,810	\$ 82,312	\$ (7,561)	\$ (81,924)	\$ 249	\$ 388	\$ 637	\$	\$
	\$ 341,192	\$ 296,460	\$ 466,861	\$ 178,433	\$ 311,660	\$ 474,893	\$ 778,521	\$ 1,253,414	\$ 289,473	

S-3

Table of Contents

SCHEDULE III

(page 4 of 4)

## COUSINS PROPERTIES INCORPORATED AND SUBSIDIARIES

## REAL ESTATE AND ACCUMULATED DEPRECIATION

DECEMBER 31, 2011

(in thousands)

## NOTES:

- (a) Reconciliations of total real estate carrying value and accumulated depreciation for the three years ended December 31, 2011 are as follows:

	000000 2011	000000 Real Estate 2010	000000 2009	000000 Accumulated Depreciation 2011	000000 2010	000000 2009
Balance at beginning of period	\$ 1,363,320	\$ 1,468,413	\$ 1,458,001	\$ 274,925	\$ 233,091	\$ 186,252
Additions during the period:						
Acquisition	116,229					
Improvements and other capitalized costs	50,009	43,798	83,211			
Depreciation expense				52,630	58,585	52,926
	166,238	43,798	83,211	52,630	58,585	52,926
Deductions during the period:						
Cost of real estate sold or foreclosed	(162,989)	(143,497)	(31,908)	(29,110)	(13,911)	(96)
Impairment losses	(104,183)	(2,554)	(34,900)			
Write-off of fully depreciated assets	(8,972)	(2,840)	(5,991)	(8,972)	(2,840)	(5,991)
	(276,144)	(148,891)	(72,799)	(38,082)	(16,751)	(6,087)
Balance at end of period	\$ 1,253,414	\$ 1,363,320	\$ 1,468,413	\$ 289,473	\$ 274,925	\$ 233,091

- (b) Buildings and improvements are depreciated over 24 to 40 years. Leasehold improvements and other capitalized leasing costs are depreciated over the life of the asset or the term of the lease, whichever is shorter.
- (c) 100 North Point Center East and 200 North Point Center East were financed together with such properties being collateral for one non-recourse mortgage note payable.

Edgar Filing: JUNIPER PHARMACEUTICALS INC - Form SC TO-T

- (d) Certain intangible assets related to the purchase of this property are included in other assets and are not in the above table.

S-4